Patents by Inventor Vadim Dudkin

Vadim Dudkin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220289785
    Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.
    Type: Application
    Filed: July 28, 2021
    Publication date: September 15, 2022
    Inventors: David TELLERS, Steven L. COLLETTI, Vadim DUDKIN, Jeffrey AARONSON, Aaron MOMOSE, Thomas Joseph TUCKER, Yu YUAN, Kathleen B. CALATI, Lu TIAN, Rubina G. PARMAR, Anthony W. SHAW, Weimin WANG, Rachel Anne STORR, Marina BUSUEK, Robert A. KOWTONIUK
  • Publication number: 20210388085
    Abstract: Engineered antibodies useful for site-specific conjugation by a transglutaminase are described. Also described are methods of site-specific conjugation of the antibodies, the site-specifically conjugated antibodies, and pharmaceutical compositions and uses related to the site-specifically conjugated antibodies.
    Type: Application
    Filed: May 19, 2021
    Publication date: December 16, 2021
    Inventors: Vadim Dudkin, Shalom Goldberg, Michael J. McCauley, Kristen Wiley, Rebecca Wissner
  • Publication number: 20210363177
    Abstract: Provided herein are methods for site-specific conjugation of glycan intact antibodies by a transglutaminase. According to particular embodiments, the reaction conditions are maintained or reduced to a low-ionic strength condition, which allows for efficient and fast conjugation without the need for antibody deglycosylation. Also described are pharmaceutical compositions and uses related to the conjugation method.
    Type: Application
    Filed: May 19, 2021
    Publication date: November 25, 2021
    Inventors: Vadim Dudkin, Shalom Goldberg, Michael J. McCauley, Kristen Wiley
  • Patent number: 11117917
    Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: September 14, 2021
    Assignee: Sirna Therapeutics, Inc.
    Inventors: David Tellers, Steven L. Colletti, Vadim Dudkin, Jeffrey Aaronson, Aaron Momose, Thomas Joseph Tucker, Yu Yuan, Kathleen B. Calati, Lu Tian, Rubina G. Parmar, Anthony W. Shaw, Weimin Wang, Rachel Anne Storr, Marina Busuek, Robert A. Kowtoniuk
  • Publication number: 20210017099
    Abstract: Improved methods of radiolabeling antibodies using click chemistry are described. Also described are pharmaceutical compositions and uses related to the radiolabeled antibodies produced by the methods.
    Type: Application
    Filed: December 17, 2018
    Publication date: January 21, 2021
    Inventors: Vadim Dudkin, Shalom Goldberg, Joseph Erhardt, Rhys Salter, Theresa McDevitt
  • Publication number: 20200353105
    Abstract: Macrocyclic chelators for chelation of alpha-emitting radiometal ions, such as actinium-225 are provided. Also provided are radiometal complexes containing an alpha-emitting radiometal ion bound to the macrocyclic chelator via coordinate bonding, and radioimmunoconjugates containing the radiometal complexes covalently linked to a targeting ligand, such as an antibody or antigen binding fragment thereof. The radioimmunoconjugates can be produced by click chemistry reactions. Methods of using the radiocomplexes and radioimmunoconjugates for selectively targeting neoplastic cells for radiotherapy and for treating neoplastic diseases and disorders are also described.
    Type: Application
    Filed: May 8, 2020
    Publication date: November 12, 2020
    Inventors: Rhys Salter, Vadim Dudkin, Fengbin Song, Wei Zhang, Shalom Goldberg, John Keith
  • Publication number: 20190184028
    Abstract: A fibronectin type III (FN3) domain-nanoparticle or direct conjugate complex containing a polynucleotide molecule, a toxin, polynucleotide molecule or other pharmaceutically active payload is obtained by panning an FN3 domain library with a protein or nucleotide of interest, recovering the FN3 domain and conjugating the FN3 domain with a toxin or nanoparticle containing an active polynucleotide, such as an ASO or siRNA molecule. A fibronectin type III (FN3) domain-nucleic acid conjugate is obtained by panning an FN3 domain library with a protein or nucleotide of interest, recovering the FN3 domain and conjugating the FN3 domain to a nucleic acid (e.g., ASO or siRNA). The nanoparticle complex, nucleic acid conjugate or FN3 domain toxin conjugate may be used in the treatment of diseases and conditions, for example, oncology or auto-immune indications.
    Type: Application
    Filed: December 13, 2018
    Publication date: June 20, 2019
    Inventors: Vadim Dudkin, Andrew Elias, Shalom Goldberg, Donna Klein, Elise Kuhar, Tricia Lin, Lavanya Peddada, Karyn O'Neil, Kristen Wiley
  • Publication number: 20190153016
    Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.
    Type: Application
    Filed: February 5, 2019
    Publication date: May 23, 2019
    Inventors: David TELLERS, Steven L. COLLETTI, Vadim DUDKIN, Jeffrey AARONSON, Aaron MOMOSE, Thomas Joseph TUCKER, Yu YUAN, Kathleen B. CALATI, Lu TIAN, Rubina G. PARMAR, Anthony W. SHAW, Weimin WANG, Rachel Anne STORR, Marina BUSUEK, Robert A. KOWTONIUK
  • Patent number: 10221205
    Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: March 5, 2019
    Assignee: Sirna Therapeutics, Inc.
    Inventors: David Tellers, Steven L. Colletti, Vadim Dudkin, Jeffrey Aaronson, Aaron Momose, Thomas Joseph Tucker, Yu Yuan, Kathleen B. Calati, Lu Tian, Rubina G. Parmar, Anthony W. Shaw, Weimin Wang, Rachel Anne Storr, Marina Busuek, Robert A. Kowtoniuk
  • Patent number: 10214742
    Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; and optionally, 4) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: February 26, 2019
    Assignee: Sima Therapeutics, Inc.
    Inventors: David Tellers, Steven Colletti, Vadim Dudkin, Norihiro Ikemoto, Hongbiao Liao, Craig Parish, Tao Pei, Anthony Shaw, Quang Truong, Lijun Wang, Yu Yuan, Man Zhu
  • Publication number: 20180079769
    Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.
    Type: Application
    Filed: November 8, 2017
    Publication date: March 22, 2018
    Inventors: David TELLERS, Steven L. COLLETTI, Vadim DUDKIN, Jeffrey AARONSON, Aaron MOMOSE, Thomas Joseph TUCKER, Yu YUAN, Kathleen B. CALATI, Lu TIAN, Rubina G. PARMAR, Anthony W. SHAW, Weimin WANG, Rachel Anne STORR, Marina BUSUEK, Robert A. KOWTONIUK
  • Patent number: 9840531
    Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: December 12, 2017
    Assignee: Sirna Therapeutics, Inc.
    Inventors: David Tellers, Steven L. Colletti, Vadim Dudkin, Jeffrey Aaronson, Aaron Momose, Thomas Joseph Tucker, Yu Yuan, Kathleen B. Calati, Lu Tian, Rubina G. Parmar, Anthony W. Shaw, Weimin Wang, Rachel Anne Storr, Marina Busuek, Robert A. Kowtoniuk
  • Publication number: 20170306324
    Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.
    Type: Application
    Filed: April 7, 2017
    Publication date: October 26, 2017
    Inventors: David TELLERS, Steven L. COLLETTI, Vadim DUDKIN, Jeffrey AARONSON, Aaron MOMOSE, Thomas Joseph TUCKER, Yu YUAN, Kathleen B. CALATI, Lu TIAN, Rubina G. PARMAR, Anthony W. SHAW, Weimin WANG, Rachel Anne STORR, Marina BUSUEK, Robert A. KOWTONIUK
  • Publication number: 20170233731
    Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; and optionally, 4) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.
    Type: Application
    Filed: November 29, 2016
    Publication date: August 17, 2017
    Inventors: David TELLERS, Steven COLLETTI, Vadim DUDKIN, Norihiro IKEMOTO, Hongbiao LIAO, Craig PARISH, Tao PEI, Anthony SHAW, Quang TRUONG, Lijun WANG, Yu YUAN, Man ZHU
  • Patent number: 9655976
    Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: May 23, 2017
    Assignee: Sirna Therapeutics, Inc.
    Inventors: David Tellers, Steven L. Colletti, Vadim Dudkin, Jeffrey Aaronson, Aaron Momose, Thomas Joseph Tucker, Yu Yuan, Kathleen B. Calati, Lu Tian, Rubina G. Parmar, Anthony W. Shaw, Weimin Wang, Rachel Anne Storr, Marina Busuek, Robert A. Kowtoniuk
  • Patent number: 9540639
    Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; and optionally, 4) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: January 10, 2017
    Assignee: Sirna Therapeutics, Inc.
    Inventors: David Tellers, Steven Colletti, Vadim Dudkin, Norihiro Ikemoto, Hongbiao Liao, Craig Parish, Tao Pei, Anthony Shaw, Quang Truong, Lijun Wang, Yu Yuan, Man Zhu
  • Publication number: 20150246133
    Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.
    Type: Application
    Filed: May 1, 2013
    Publication date: September 3, 2015
    Inventors: David Tellers, Steven L. Colletti, Vadim Dudkin, Jeffrey Aaronson, Aaron Momose, Thomas Joseph Tucker, Yu Yuan, Kathleen B. Calati, Lu Tian, Rubina G. Parmar, Anthony W. Shaw, Weimin Wang, Rachel Anne Storr, Marina Busuek, Robert A. Kowtoniuk
  • Publication number: 20150203843
    Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; and optionally, 4) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.
    Type: Application
    Filed: May 1, 2013
    Publication date: July 23, 2015
    Inventors: David Tellers, Steven Colletti, Vadim Dudkin, Norihiro Ikemoto, Hongbiao Liao, Craig Parish, Tao Pei, Anthony Shaw, Quang Truong, Lijun Wang, Yu Yuan, Man Zhu
  • Patent number: 8785481
    Abstract: The present invention is directed to ether benzotriazole derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
    Type: Grant
    Filed: September 28, 2011
    Date of Patent: July 22, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Douglas C. Beshore, Vadim Dudkin, Robert M. Garbaccio, Adam W. Johnson, Scott D. Kuduk, Jason W. Skudlarek, Cheng Wang, Mark E. Fraley
  • Patent number: 8765784
    Abstract: The present invention is directed to 5-substituted 1,3-dihydro-2H-imidazo[4,5-b]pyridine-2-one derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 receptor is involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved, such as schizophrenia.
    Type: Grant
    Filed: June 6, 2011
    Date of Patent: July 1, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kenneth L. Arrington, Vadim Dudkin, Mark E. Layton, Joseph E. Pero, Alexander J. Reif